Personalized Exosome-Based Therapy and Next-Generation MSC-Derived Exosomes
Legal Citation
Summary of the Inventive Concept
A next-generation system for personalized exosome-based therapy, leveraging real-time patient response data, predictive analytics, and advanced MSC-derived exosome engineering to revolutionize the treatment of immune-mediated inflammatory diseases.
Background and Problem Solved
The original patent disclosed the use of MSC-derived exosomes for treating immune-mediated inflammatory diseases, but it had limitations in terms of personalized treatment and exosome potency. The new inventive concept addresses these limitations by introducing a system that updates in real-time, selects optimal treatment regimens, and generates exosomes with enhanced therapeutic potency.
Detailed Description of the Inventive Concept
The new inventive concept comprises a database of patient-specific MSC-derived exosomes, a computer algorithm for selecting an optimal exosome treatment regimen, and a method for generating MSC-derived exosomes with enhanced therapeutic potency by culturing MSCs in a three-dimensional microenvironment. The system also includes a composition of matter comprising engineered exosomes, a device for real-time monitoring of exosome biodistribution and pharmacokinetics, and a method for inducing tolerance to MSC-derived exosomes. These components work together to provide a personalized and effective treatment for immune-mediated inflammatory diseases.
Novelty and Inventive Step
The new claims introduce a paradigm shift in exosome-based therapy by leveraging real-time data, predictive analytics, and advanced exosome engineering. The inventive concept's novelty lies in its ability to provide personalized treatment, enhance exosome potency, and induce tolerance to exosomes, which are not addressed by the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different types of stem cells, various methods for exosome engineering, and diverse routes of administration. Additionally, the system could be adapted for treating other diseases beyond immune-mediated inflammatory diseases.
Potential Commercial Applications and Market
The new inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the area of personalized medicine. The target market includes pharmaceutical companies, biotech startups, and research institutions focused on developing innovative treatments for immune-mediated inflammatory diseases.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Regenerative medicine and cell-based therapeutics, specifically focusing on mesenchymal stem cell (MSC) derived exosome technologies for treating immune-mediated inflammatory diseases
Person of Ordinary Skill (PHOSITA) Profile
A biomedical researcher or biotechnology engineer with expertise in stem cell biology, exosome engineering, immunology, and therapeutic development, holding at least a PhD or equivalent advanced research experience
Obviousness Rationale
A PHOSITA would recognize that the PTD's disclosed personalized exosome therapy system represents a predictable extension of the source patent's foundational work on MSC-derived exosomes. The variations introduce incremental improvements in exosome characterization, engineering, and administration that would be considered routine optimization within the field. The core therapeutic approach remains fundamentally consistent with the original patent's teachings about using MSC-derived exosomes for treating immune-mediated inflammatory diseases.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,575 |
|---|---|
| Title | Mesenchymal stem cell-derived exosomes and their uses |
| Assignee(s) | Ono Pharmaceutical Co., Ltd. |